Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534389 | 0.79 | CDK2 (0.40) | DPP4XDHCDK2PDPK1GDA | |
| SCHEMBL1233712 | 0.79 | PDPK1 (0.59) | DPP4XDHCDK2PDPK1GDA | |
| SCHEMBL3136203 | 0.79 | CDK2 (0.40) | DPP4XDHCDK2PDPK1GDA | |
| SCHEMBL356178 | 0.76 | DPP4 (0.61) | DPP4XDHCDK2PDPK1GDA | |
| SCHEMBL37384 | 0.75 | DPP4 (0.66) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL4525061 | 0.75 | CDK2 (0.38) | DPP4XDHCDK2PDPK1GDA | |
| SCHEMBL3137133 | 0.75 | XDH (0.59) | XDHCDK2ADORA3BRAF | |
| SCHEMBL4523841 | 0.75 | CDK2 (0.51) | DPP4XDHCDK2PDPK1GDA | |
| SCHEMBL4525142 | 0.75 | PDPK1 (0.51) | CDK2PDPK1POLA1ADORA3CTSS | |
| SCHEMBL4532007 | 0.75 | CDK2 (0.42) | XDHCDK2PDPK1GDAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119912510-A | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-114395005-B | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2024-10-24 | — | — | US | disclosed |
| CN-108697719-B | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4306525-A2 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-114395005-A | Modulators of extracellular 5' -nucleotidase and uses thereof | 艾库斯生物科学有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-1551837-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | disclosed |
| CN-1501927-A | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | 记忆药物公司 | 2004-06-02 | — | — | CN | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014911-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | disclosed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | DPP4 849/4885XDH 280/4885CDK2 4092/4885 |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | DPP4 863/4885XDH 280/4885CDK2 4053/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | DPP4 30/4885XDH 259/4885CDK2 1035/4885 |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | DPP4 30/4885XDH 259/4885CDK2 1035/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | DPP4 30/4885XDH 259/4885CDK2 1035/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | DPP4 863/4885XDH 280/4885CDK2 4053/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | DPP4 2200/4885XDH 57/4885CDK2 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.